scholarly journals Prognostic Value of Circulating Tumor Cells in Early Breast Cancer Patients Detected by RT-PCR of Mamaglobin

2012 ◽  
Vol 23 ◽  
pp. ix111-ix112
Author(s):  
A.M. Hilal ◽  
H.M. Elzawahrey ◽  
A.A. Abd Elwahab ◽  
M.N. Abdelhafez ◽  
M.M. Moneer ◽  
...  
2017 ◽  
Vol 33 ◽  
pp. 28-34 ◽  
Author(s):  
Georgios Z. Papadakis ◽  
Dimitrios Mavroudis ◽  
Vasilios Georgoulias ◽  
John Souglakos ◽  
Athanasios K. Alegakis ◽  
...  

2018 ◽  
Vol 171 (3) ◽  
pp. 571-580 ◽  
Author(s):  
Emanuel C. A. Bauer ◽  
◽  
Fabienne Schochter ◽  
Peter Widschwendter ◽  
Amelie DeGregorio ◽  
...  

2012 ◽  
Vol 48 ◽  
pp. S130 ◽  
Author(s):  
B. Jäger ◽  
B. Rack ◽  
C. Schindlbeck ◽  
R. Lorenz ◽  
H. Tesch ◽  
...  

2019 ◽  
Vol 3 (2) ◽  
Author(s):  
Laura Thery ◽  
Alessandra Meddis ◽  
Luc Cabel ◽  
Charlotte Proudhon ◽  
Aurelien Latouche ◽  
...  

AbstractCirculating tumor cells (CTCs) are particularly rare in non-metastatic breast cancer, and the clinical validity of CTC detection in that clinical setting was initially not well recognized. A cytological CTC detection device (CellSearch) fulfilling the CLIA requirements for analytical validity was subsequently developed and, in 2008, we reported the first study (REMAGUS02) showing that distant metastasis-free survival was shorter in early breast cancer patients with one or more CTCs. In the past 10 years, other clinical studies and meta-analyses have established CTC detection as a level-of-evidence 1 prognostic biomarker for local relapses, distant relapses, and overall survival. This review summarizes available data on CTC detection and the promises of this proliferation- and subtype-independent metastasis-associated biomarker in early breast cancer patients.


2017 ◽  
Vol 58 (1) ◽  
pp. 19 ◽  
Author(s):  
Hyung Seok Park ◽  
Hyun Ju Han ◽  
Soohyeon Lee ◽  
Gun Min Kim ◽  
Seho Park ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document